{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:39:21Z","timestamp":1787740761671,"version":"build-2784847793"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"vor","delay-in-days":84,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"publisher","award":["MGU0548"],"award-info":[{"award-number":["MGU0548"]}],"id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.smim.2022.101603","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T02:25:27Z","timestamp":1648175127000},"page":"101603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Translational advances of melanocortin drugs: Integrating biology, chemistry and genetics"],"prefix":"10.1016","volume":"59","author":[{"given":"Trinidad","family":"Montero-Melendez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Boesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.N.","family":"Jonassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5074","key":"10.1016\/j.smim.2022.101603_bib1","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1126\/science.1325670","article-title":"The cloning of a family of genes that encode the melanocortin receptors","volume":"257","author":"Mountjoy","year":"1992","journal-title":"Science"},{"issue":"19","key":"10.1016\/j.smim.2022.101603_bib2","doi-asserted-by":"crossref","first-page":"8856","DOI":"10.1073\/pnas.90.19.8856","article-title":"Identification of a receptor for gamma melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system","volume":"90","author":"Roselli-Rehfuss","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.smim.2022.101603_bib3","first-page":"1298","article-title":"Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain","volume":"8","author":"Mountjoy","year":"1994","journal-title":"Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/BF00995160","article-title":"Cloning, expression, and tissue distribution of a fifth melanocortin receptor subtype","volume":"20","author":"Fathi","year":"1995","journal-title":"Neurochem. Res."},{"issue":"2498","key":"10.1016\/j.smim.2022.101603_bib5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1126\/science.96.2498.450","article-title":"Isolation of adrenocorticotropic hormone from sheep pituitaries","volume":"96","author":"Li","year":"1942","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.smim.2022.101603_bib6","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/art.10526","article-title":"Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis","volume":"46","author":"Getting","year":"2002","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ajpath.2011.03.042","article-title":"The melanocortin agonist AP214 exerts anti-inflammatory and proresolving properties","volume":"179","author":"Montero-Melendez","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.smim.2022.101603_bib8","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.4049\/jimmunol.1402645","article-title":"Biased agonism as a novel strategy to harness the proresolving properties of melanocortin receptors without eliciting melanogenic effects","volume":"194","author":"Montero-Melendez","year":"2015","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.smim.2022.101603_bib9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.tips.2015.07.007","article-title":"Resolution pharmacology: opportunities for therapeutic innovation in inflammation","volume":"36","author":"Perretti","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.smim.2022.101603_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.smim.2015.02.003","article-title":"ACTH: the forgotten therapy","volume":"27","author":"Montero-Melendez","year":"2015","journal-title":"Semin. Immunol."},{"issue":"3","key":"10.1016\/j.smim.2022.101603_bib11","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1210\/mend.11.3.9898","article-title":"Effects of recombinant agouti-signaling protein on melanocortin action","volume":"11","author":"Yang","year":"1997","journal-title":"Mol. Endocrinol."},{"issue":"5335","key":"10.1016\/j.smim.2022.101603_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1126\/science.278.5335.135","article-title":"Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein","volume":"278","author":"Ollmann","year":"1997","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib13","first-page":"164","article-title":"AgRP(83-132) acts as an inverse agonist on the human-melanocortin-4 receptor","volume":"15","author":"Nijenhuis","year":"2001","journal-title":"Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-0115(01)00234-8","article-title":"Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor","volume":"99","author":"Haskell-Luevano","year":"2001","journal-title":"Regul. Pept."},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1081\/RRS-100107140","article-title":"Antagonist and agonist activities of the mouse agouti protein fragment (91-131) at the melanocortin-1 receptor","volume":"21","author":"Eberle","year":"2001","journal-title":"J. Recept. Signal. Transduct. Res."},{"issue":"39","key":"10.1016\/j.smim.2022.101603_bib16","doi-asserted-by":"crossref","first-page":"26411","DOI":"10.1074\/jbc.M109.039339","article-title":"Pertussis toxin-sensitive signaling of melanocortin-4 receptors in hypothalamic GT1-7 cells defines agouti-related protein as a biased agonist","volume":"284","author":"Buch","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.smim.2022.101603_bib17","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1755-148X.2009.00582.x","article-title":"Agouti protein, mahogunin, and attractin in pheomelanogenesis and melanoblast-like alteration of melanocytes: a cAMP-independent pathway","volume":"22","author":"Hida","year":"2009","journal-title":"Pigment Cell Melanoma Res."},{"issue":"6143","key":"10.1016\/j.smim.2022.101603_bib18","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1126\/science.1233000","article-title":"Loss of function of the melanocortin 2 receptor accessory protein 2 is associated with mammalian obesity","volume":"341","author":"Asai","year":"2013","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.smim.2022.101603_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1210\/me.2009-0283","article-title":"Minireview: the melanocortin 2 receptor accessory proteins","volume":"24","author":"Webb","year":"2010","journal-title":"Mol. Endocrinol."},{"issue":"4","key":"10.1016\/j.smim.2022.101603_bib20","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1755-148X.2010.00721.x","article-title":"Shades of meaning: the pigment-type switching system as a tool for discovery","volume":"23","author":"Walker","year":"2010","journal-title":"Pigment Cell Melanoma Res."},{"issue":"11","key":"10.1016\/j.smim.2022.101603_bib21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrd.2018.135","article-title":"Targeting G protein-coupled receptor signalling by blocking G proteins","volume":"17","author":"Campbell","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.smim.2022.101603_bib22","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3389\/fphar.2019.00125","article-title":"GPCR signaling regulation: the role of GRKs and arrestins","volume":"10","author":"Gurevich","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.smim.2022.101603_bib23","doi-asserted-by":"crossref","first-page":"15054","DOI":"10.1038\/ncomms15054","article-title":"A new inhibitor of the beta-arrestin\/AP2 endocytic complex reveals interplay between GPCR internalization and signalling","volume":"8","author":"Beautrait","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2022.101603_bib24","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.phrs.2016.05.008","article-title":"The expanding GRK interactome: implications in cardiovascular disease and potential for therapeutic development","volume":"110","author":"Hullmann","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"45","key":"10.1016\/j.smim.2022.101603_bib25","doi-asserted-by":"crossref","first-page":"16587","DOI":"10.1074\/jbc.RA119.009160","article-title":"Design and development of stapled transmembrane peptides that disrupt the activity of G-protein-coupled receptor oligomers","volume":"294","author":"Botta","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.smim.2022.101603_bib26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.bbrc.2004.11.036","article-title":"Melanocortin receptors form constitutive homo- and heterodimers","volume":"326","author":"Mandrika","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.smim.2022.101603_bib27","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.peptides.2004.12.037","article-title":"Dimerization of the melanocortin 4 receptor: a study using bioluminescence resonance energy transfer","volume":"27","author":"Nickolls","year":"2006","journal-title":"Peptides"},{"issue":"7","key":"10.1016\/j.smim.2022.101603_bib28","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1021\/acs.jmedchem.5b01894","article-title":"An in vitro and in vivo investigation of bivalent ligands that display preferential binding and functional activity for different melanocortin receptor homodimers","volume":"59","author":"Lensing","year":"2016","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.smim.2022.101603_bib29","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/s41573-019-0047-y","article-title":"Targeted protein degradation: expanding the toolbox","volume":"18","author":"Schapira","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.smim.2022.101603_bib30","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.apsb.2020.01.014","article-title":"First small-molecule PROTACs for G protein-coupled receptors: inducing alpha 1A-adrenergic receptor degradation","volume":"10","author":"Li","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.smim.2022.101603_bib31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygcen.2014.04.005","article-title":"Evolution of the melanocortin system","volume":"209","author":"Cortes","year":"2014","journal-title":"Gen. Comp. Endocrinol."},{"issue":"Suppl 1","key":"10.1016\/j.smim.2022.101603_bib32","first-page":"S21","article-title":"THE CONCISE GUIDE TO PHARMACOLOGY 2019\/20: G protein-coupled receptors","volume":"176","author":"Alexander","year":"2019","journal-title":"Br. J. Pharmacol."},{"issue":"7436","key":"10.1016\/j.smim.2022.101603_bib33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature11896","article-title":"Molecular signatures of G-protein-coupled receptors","volume":"494","author":"Venkatakrishnan","year":"2013","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.smim.2022.101603_bib34","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/gbe\/evu038","article-title":"The evolution of the GPCR signaling system in eukaryotes: modularity, conservation, and the transition to metazoan multicellularity","volume":"6","author":"de Mendoza","year":"2014","journal-title":"Genome Biol. Evol."},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygcen.2008.11.026","article-title":"Modeling the evolution of the MC2R and MC5R genes: studies on the cartilaginous fish, Heterondotus francisci","volume":"161","author":"Baron","year":"2009","journal-title":"Gen. Comp. Endocrinol"},{"issue":"5","key":"10.1016\/j.smim.2022.101603_bib36","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.coi.2007.07.009","article-title":"The 2R hypothesis: an update","volume":"19","author":"Kasahara","year":"2007","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.smim.2022.101603_bib37","first-page":"125","article-title":"Gene duplications and the origins of vertebrate development","author":"Holland","year":"1994","journal-title":"Dev. Suppl."},{"key":"10.1016\/j.smim.2022.101603_bib38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3389\/fnins.2013.00028","article-title":"Observations on the evolution of the melanocortin receptor gene family: distinctive features of the melanocortin-2 receptor","volume":"7","author":"Dores","year":"2013","journal-title":"Front. Neurosci."},{"issue":"11","key":"10.1016\/j.smim.2022.101603_bib39","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nrg928","article-title":"Splitting pairs: the diverging fates of duplicated genes","volume":"3","author":"Prince","year":"2002","journal-title":"Nat. Rev. Genet."},{"issue":"10","key":"10.1016\/j.smim.2022.101603_bib40","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.peptides.2004.11.034","article-title":"Evolutionary conservation of the structural, pharmacological, and genomic characteristics of the melanocortin receptor subtypes","volume":"26","author":"Schioth","year":"2005","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41467-020-14421-x","article-title":"Therapeutic senescence via GPCR activation in synovial fibroblasts facilitates resolution of arthritis","volume":"11","author":"Montero-Melendez","year":"2020","journal-title":"Nat. Commun."},{"issue":"6544","key":"10.1016\/j.smim.2022.101603_bib42","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1126\/science.abf7958","article-title":"Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling","volume":"372","author":"Israeli","year":"2021","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.smim.2022.101603_bib43","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/mol.117.111062","article-title":"G protein-coupled receptors as targets for approved drugs: how many targets and how many drugs?","volume":"93","author":"Sriram","year":"2018","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.smim.2022.101603_bib44","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/aps.2011.173","article-title":"Tools for GPCR drug discovery","volume":"33","author":"Zhang","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"issue":"6","key":"10.1016\/j.smim.2022.101603_bib45","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.copbio.2005.10.008","article-title":"Functional assays for screening GPCR targets","volume":"16","author":"Thomsen","year":"2005","journal-title":"Curr. Opin. Biotechnol."},{"issue":"7","key":"10.1016\/j.smim.2022.101603_bib46","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00018-016-2419-3","article-title":"Old drugs with new skills: fenoprofen as an allosteric enhancer at melanocortin receptor 3","volume":"74","author":"Montero-Melendez","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"issue":"6489","key":"10.1016\/j.smim.2022.101603_bib47","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.aaz8995","article-title":"Determination of the melanocortin-4 receptor structure identifies Ca(2+) as a cofactor for ligand binding","volume":"368","author":"Yu","year":"2020","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.smim.2022.101603_bib48","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/s41422-021-00557-y","article-title":"Structural mechanism of calcium-mediated hormone recognition and Gbeta interaction by the human melanocortin-1 receptor","volume":"31","author":"Ma","year":"2021","journal-title":"Cell Res."},{"issue":"6","key":"10.1016\/j.smim.2022.101603_bib49","doi-asserted-by":"crossref","first-page":"638","DOI":"10.2174\/156802610791111498","article-title":"G protein coupled receptors -in silico drug discovery and design","volume":"10","author":"Sela","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"issue":"3","key":"10.1016\/j.smim.2022.101603_bib50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd3954","article-title":"Signalling bias in new drug discovery: detection, quantification and therapeutic impact","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.smim.2022.101603_bib51","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca\u2019s drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.smim.2022.101603_bib52","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat. Genet."},{"issue":"12","key":"10.1016\/j.smim.2022.101603_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008489","article-title":"Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval","volume":"15","author":"King","year":"2019","journal-title":"PLoS Genet."},{"issue":"3","key":"10.1016\/j.smim.2022.101603_bib54","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.cell.2019.03.044","article-title":"Human gain-of-function MC4R variants show signaling bias and protect against obesity","volume":"177","author":"Lotta","year":"2019","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.smim.2022.101603_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108862","article-title":"Human MC4R variants affect endocytosis, trafficking and dimerization revealing multiple cellular mechanisms involved in weight regulation","volume":"34","author":"Brouwers","year":"2021","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib56","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1021\/acs.jmedchem.0c01620","article-title":"Structure-based design of melanocortin 4 receptor ligands based on the SHU-9119-hMC4R cocrystal structuredagger","volume":"64","author":"Martin","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib57","first-page":"E47","article-title":"Three types of alpha-melanocyte-stimulating hormone: bioactivities and half-lives","volume":"245","author":"Rudman","year":"1983","journal-title":"Am. J. Physiol."},{"issue":"14","key":"10.1016\/j.smim.2022.101603_bib58","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1021\/jm960840h","article-title":"Discovery of prototype peptidomimetic agonists at the human melanocortin receptors MC1R and MC4R","volume":"40","author":"Haskell-Luevano","year":"1997","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.smim.2022.101603_bib59","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.1073\/pnas.77.10.5754","article-title":"4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity","volume":"77","author":"Sawyer","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"26","key":"10.1016\/j.smim.2022.101603_bib60","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1021\/jm000211e","article-title":"D-Amino acid scan of gamma-melanocyte-stimulating hormone: importance of Trp(8) on human MC3 receptor selectivity","volume":"43","author":"Grieco","year":"2000","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.smim.2022.101603_bib61","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1021\/jm00132a010","article-title":"Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics","volume":"32","author":"Al-Obeidi","year":"1989","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.smim.2022.101603_bib62","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1021\/jm00018a005","article-title":"Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors","volume":"38","author":"Hruby","year":"1995","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.smim.2022.101603_bib63","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1021\/jm990190s","article-title":"Compounds that activate the mouse melanocortin-1 receptor identified by screening a small molecule library based upon the beta-turn","volume":"42","author":"Haskell-Luevano","year":"1999","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.smim.2022.101603_bib64","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1021\/jm025600i","article-title":"Discovery of tyrosine-based potent and selective melanocortin-1 receptor small-molecule agonists with anti-inflammatory properties","volume":"46","author":"Herpin","year":"2003","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.smim.2022.101603_bib65","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1021\/jm025539h","article-title":"Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium- 3-ylcarbonyl]-(1R)-1-(4-chlorobenzyl)- 2-[4-cyclohexyl-4-(1H-1,2,4-triazol- 1-ylmethyl)piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist","volume":"45","author":"Sebhat","year":"2002","journal-title":"J. Med. Chem."},{"issue":"10 Pt A","key":"10.1016\/j.smim.2022.101603_bib66","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.bbadis.2017.03.020","article-title":"Bench-top to clinical therapies: a review of melanocortin ligands from 1954 to 2016","volume":"1863","author":"Ericson","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"2","key":"10.1016\/j.smim.2022.101603_bib67","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1172\/JCI10628","article-title":"Haploinsufficiency of the melanocortin-4 receptor: part of a thrifty genotype?","volume":"106","author":"Cone","year":"2000","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib68","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejphar.2011.01.031","article-title":"Development of a high throughput screen for allosteric modulators of melanocortin-4 receptor signaling using a real time cAMP assay","volume":"660","author":"Pantel","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"7109","key":"10.1016\/j.smim.2022.101603_bib69","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature05098","article-title":"Topical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning","volume":"443","author":"D'Orazio","year":"2006","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.smim.2022.101603_bib70","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1016\/j.febslet.2009.09.023","article-title":"Melanocortin 1 receptor mutations impact differentially on signalling to the cAMP and the ERK mitogen-activated protein kinase pathways","volume":"583","author":"Herraiz","year":"2009","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.smim.2022.101603_bib71","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00008390-200209000-00001","article-title":"Skin colour and skin cancer - MC1R, the genetic link","volume":"12","author":"Sturm","year":"2002","journal-title":"Melanoma Res."},{"issue":"5","key":"10.1016\/j.smim.2022.101603_bib72","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1074\/jbc.M606865200","article-title":"Regulation of human melanocortin 1 receptor signaling and trafficking by Thr-308 and Ser-316 and its alteration in variant alleles associated with red hair and skin cancer","volume":"282","author":"Sanchez-Laorden","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.smim.2022.101603_bib73","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.peptides.2007.10.003","article-title":"Human melanocytes expressing MC1R variant alleles show impaired activation of multiple signaling pathways","volume":"28","author":"Newton","year":"2007","journal-title":"Peptides"},{"issue":"18","key":"10.1016\/j.smim.2022.101603_bib74","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/hmg\/ddm177","article-title":"Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles","volume":"16","author":"Beaumont","year":"2007","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.smim.2022.101603_bib75","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1124\/jpet.112.194548","article-title":"Selected melanocortin 1 receptor single-nucleotide polymorphisms differentially alter multiple signaling pathways","volume":"342","author":"Doyle","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.smim.2022.101603_bib76","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/nrd2593","article-title":"Pharmacogenetics in drug discovery and development: a translational perspective","volume":"7","author":"Roses","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.smim.2022.101603_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092667","article-title":"MC1R: front and center in the bright side of dark eumelanin and DNA repair","volume":"19","author":"Swope","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.smim.2022.101603_bib78","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/pcmr.12252","article-title":"Significance of the melanocortin 1 receptor in the DNA damage response of human melanocytes to ultraviolet radiation","volume":"27","author":"Swope","year":"2014","journal-title":"Pigment Cell Melanoma Res."},{"issue":"1\u20132","key":"10.1016\/j.smim.2022.101603_bib79","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.mce.2014.07.003","article-title":"Development of potent selective competitive-antagonists of the melanocortin type 2 receptor","volume":"394","author":"Bouw","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.smim.2022.101603_bib80","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fendo.2017.00017","article-title":"From bioinactive ACTH to ACTH antagonist: the clinical perspective","volume":"8","author":"Ghaddhab","year":"2017","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.smim.2022.101603_bib81","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3389\/fendo.2016.00101","article-title":"ACTH antagonists","volume":"7","author":"Clark","year":"2016","journal-title":"Front. Endocrinol."},{"issue":"8","key":"10.1016\/j.smim.2022.101603_bib82","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/obr.12864","article-title":"Loss-of-function mutations in the melanocortin-3 receptor gene confer risk for human obesity: a systematic review and meta-analysis","volume":"20","author":"Ehtesham","year":"2019","journal-title":"Obes. Rev."},{"key":"10.1016\/j.smim.2022.101603_bib83","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3389\/fnins.2017.00128","article-title":"A life without hunger: the ups (and downs) to modulating melanocortin-3 receptor signaling","volume":"11","author":"Butler","year":"2017","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.smim.2022.101603_bib84","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1749-6632.2003.tb03186.x","article-title":"Knockout studies defining different roles for melanocortin receptors in energy homeostasis","volume":"994","author":"Butler","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9","key":"10.1016\/j.smim.2022.101603_bib85","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1172\/JCI138392","article-title":"Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia","volume":"130","author":"Zhu","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"590","key":"10.1016\/j.smim.2022.101603_bib86","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd6434","article-title":"The melanocortin-3 receptor is a pharmacological target for the regulation of anorexia","volume":"13","author":"Sweeney","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"7885","key":"10.1016\/j.smim.2022.101603_bib87","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41586-021-04088-9","article-title":"MC3R links nutritional state to childhood growth and the timing of puberty","volume":"599","author":"Lam","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.smim.2022.101603_bib88","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1189\/jlb.0706426","article-title":"The melanocortin system in leukocyte biology","volume":"81","author":"Catania","year":"2007","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.smim.2022.101603_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108232","article-title":"Novel hybrid compounds, opioid agonist+melanocortin 4 receptor antagonist, as efficient analgesics in mouse chronic constriction injury model of neuropathic pain","volume":"178","author":"Starnowska-Sokol","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.smim.2022.101603_bib90","first-page":"1","article-title":"Melanocortin 5 receptor expression and recovery of ocular immune privilege after uveitis","author":"Ng","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.smim.2022.101603_bib91","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-1-4419-6354-3_6","article-title":"Melanocortins and the cholinergic anti-inflammatory pathway","volume":"681","author":"Giuliani","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.smim.2022.101603_bib92","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.651236","article-title":"Melanocortin system in kidney homeostasis and disease: novel therapeutic opportunities","volume":"12","author":"Chang","year":"2021","journal-title":"Front. Physiol."},{"issue":"9","key":"10.1016\/j.smim.2022.101603_bib93","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1161\/ATVBAHA.115.305348","article-title":"Both MC1 and MC3 receptors provide protection from cerebral ischemia-reperfusion-induced neutrophil recruitment","volume":"35","author":"Holloway","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.smim.2022.101603_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126179","article-title":"Brain protein expression profile confirms the protective effect of the ACTH(4-7)PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion","volume":"22","author":"Sudarkina","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.smim.2022.101603_bib95","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2009.11.003","article-title":"Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model","volume":"138","author":"Laroui","year":"2010","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.smim.2022.101603_bib96","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1096\/fj.201600790R","article-title":"Melanocortin agonism as a viable strategy to control alveolar bone loss induced by oral infection","volume":"30","author":"Madeira","year":"2016","journal-title":"FASEB J."},{"issue":"8","key":"10.1016\/j.smim.2022.101603_bib97","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.ajpath.2014.04.009","article-title":"Association between periodontal disease and inflammatory arthritis reveals modulatory functions by melanocortin receptor type 3","volume":"184","author":"Montero-Melendez","year":"2014","journal-title":"Am. J. Pathol."},{"issue":"7","key":"10.1016\/j.smim.2022.101603_bib98","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1507\/endocrj.EJ21-0002","article-title":"Role of chronic inflammation in the pathogenesis of nonalcoholic steatohepatitis: lessons from a unique mouse model using melanocortin receptor-deficient mice","volume":"68","author":"Itoh","year":"2021","journal-title":"Endocr. J."},{"key":"10.1016\/j.smim.2022.101603_bib99","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejphar.2014.10.022","article-title":"Protective effects of the melanocortin analog NDP-alpha-MSH in rats undergoing cardiac arrest","volume":"745","author":"Ottani","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.smim.2022.101603_bib100","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1189\/jlb.0306175","article-title":"MC-3 receptor and the inflammatory mechanisms activated in acute myocardial infarct","volume":"76","author":"Getting","year":"2004","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.smim.2022.101603_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2021.170552","article-title":"NDP-MSH treatment recovers marginal lungs during ex vivo lung perfusion (EVLP)","volume":"141","author":"Lonati","year":"2021","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib102","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1038\/s41598-021-83932-4","article-title":"Melanocortin receptor activation alleviates amyloid pathology and glial reactivity in an Alzheimer\u2019s disease transgenic mouse model","volume":"11","author":"Lau","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib103","doi-asserted-by":"crossref","first-page":"7277","DOI":"10.1038\/s41598-020-64305-9","article-title":"Anti-inflammatory effects of alpha-MSH through p-CREB expression in sarcoidosis like granuloma model","volume":"10","author":"Zhang","year":"2020","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.smim.2022.101603_bib104","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archinte.1950.00230100002001","article-title":"Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions","volume":"85","author":"Hench","year":"1950","journal-title":"Arch. Intern. Med."},{"issue":"9","key":"10.1016\/j.smim.2022.101603_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101487","article-title":"Mechanism of action and target identification: a matter of timing in drug discovery","volume":"23","author":"Davis","year":"2020","journal-title":"iScience"},{"issue":"28","key":"10.1016\/j.smim.2022.101603_bib106","doi-asserted-by":"crossref","first-page":"11178","DOI":"10.1073\/pnas.1204524109","article-title":"Identifying mechanism-of-action targets for drugs and probes","volume":"109","author":"Gregori-Puigjane","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.smim.2022.101603_bib107","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jbspin.2012.09.009","article-title":"ACTH as first line treatment for acute gout in 181 hospitalized patients","volume":"80","author":"Daoussis","year":"2013","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.smim.2022.101603_bib108","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11926-011-0163-0","article-title":"Role of melanocortin receptors in the regulation of gouty inflammation","volume":"13","author":"Montero-Melendez","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"issue":"12","key":"10.1016\/j.smim.2022.101603_bib109","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","article-title":"Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials","volume":"8","author":"Clement","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"10.1016\/j.smim.2022.101603_bib110","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s40265-021-01470-9","article-title":"Setmelanotide: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.smim.2022.101603_bib111","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/AOG.0000000000003514","article-title":"Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder","volume":"134","author":"Simon","year":"2019","journal-title":"Obstet. Gynecol."},{"issue":"27","key":"10.1016\/j.smim.2022.101603_bib112","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1038\/s41388-018-0216-1","article-title":"cAMP-independent non-pigmentary actions of variant melanocortin 1 receptor: AKT-mediated activation of protective responses to oxidative DNA damage","volume":"37","author":"Castejon-Grinan","year":"2018","journal-title":"Oncogene"},{"issue":"7672","key":"10.1016\/j.smim.2022.101603_bib113","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature23887","article-title":"Palmitoylation-dependent activation of MC1R prevents melanomagenesis","volume":"549","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.smim.2022.101603_bib114","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","author":"Baughman","year":"2021","journal-title":"Eur. Respir. J."},{"issue":"6","key":"10.1016\/j.smim.2022.101603_bib115","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0092-8674(00)80467-5","article-title":"Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides","volume":"91","author":"Chen","year":"1997","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.smim.2022.101603_bib116","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.peptides.2005.05.030","article-title":"Melanocortin-5 receptor: a marker of human sebocyte differentiation","volume":"27","author":"Zhang","year":"2006","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib117","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ejphar.2010.10.100","article-title":"Melanocortin-5 receptor and sebogenesis","volume":"660","author":"Zhang","year":"2011","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib118","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1468-3083.2012.04658.x","article-title":"Beneficial effects of the melanocortin analogue Nle4-D-Phe7-alpha-MSH in acne vulgaris","volume":"28","author":"Bohm","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.smim.2022.101603_bib119","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.3389\/fphar.2018.01535","article-title":"Probing the role of melanocortin type 1 receptor agonists in diverse immunological diseases","volume":"9","author":"Spana","year":"2018","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.smim.2022.101603_bib120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/ng1197-273","article-title":"Overexpression of Agrt leads to obesity in transgenic mice","volume":"17","author":"Graham","year":"1997","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.smim.2022.101603_bib121","doi-asserted-by":"crossref","DOI":"10.1002\/ski2.78","article-title":"Melanogenic effect of dersimelagon (MT-7117), a novel oral melanocortin 1 receptor agonist","volume":"2","author":"Suzuki","year":"2021","journal-title":"Skin Health Dis."}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532322000203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532322000203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:26:39Z","timestamp":1760916399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532322000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":121,"alternative-id":["S1044532322000203"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2022.101603","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translational advances of melanocortin drugs: Integrating biology, chemistry and genetics","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2022.101603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101603"}}